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We conducted a phase II study to assess activity and safety profileof bendamustine and rituximab in elderly patients withuntreated diffuse large B-cell lymphoma (DLBCL) who were
prospectively defined as frail using a simplified version of the
Comprehensive Geriatric Assessment (CGA). Patients had to be over 70
years of age, with histologically confirmed DLBCL. Frail patients were
those younger than 80 years with a frail profile at CGA or older than 80
years with an unfit profile. Treatment consisted of 4-6 courses of ben-
damustine [90 mg/m2 days (d)1-2] and rituximab (375 mg/m2 d1) admin-
istered every 28 days. Other main study end points were complete remis-
sion rate and the rate of extra-hematologic adverse events. Forty-nine
patients were enrolled of whom 45 were confirmed eligible. Overall, 24
patients achieved a complete remission (53%; 95%CI: 38-68%) and the
overall response rate was 62% (95%CI: 47-76%). The most frequent
grade 3-4 adverse event was neutropenia (37.8%). Grade 3-4 extra-hema-
tologic adverse events were observed in 7 patients (15.6%; 95%CI: 6.5-
29.5%); the most frequent  was grade 3 infection in 2 patients. With a
median follow up of 33 months (range 1-52), the median progression-free
survival was ten months (95%CI: 7-25). The study shows promising
activity and manageable toxicity profile of BR combination as first-line
therapy for patients with DLBCL who are prospectively defined as frail
according to a simplified CGA, as adopted in this trial (clinicaltrials.gov
identifier: 01990144). 
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Diffuse large B-cell lymphoma (DLBCL) is the most fre-
quent non-Hodgkin lymphoma (NHL) and typically
affects elderly patients; approximately 50% of the patients
are older than 65 years and 15% are older than 80 years.1
More importantly, life expectancy has markedly
improved over the past century and it is expected that the
number of people older than 75 years will triple by the
year 2030.2 As a consequence, the burden of age-related
diseases, including DLBCL, is expected to increase in the
near future.
R-CHOP is the undisputed standard for the treatment of
elderly patients up to 80 years of age.3 A remaining unmet
need, however, is related to the treatment of elderly
patients who, due to age or comorbidity, cannot be treated
with full-dose standard treatment. In these subjects, the
availability of less toxic regimens is strongly warranted
but the decision-making process concerning therapeutic
intervention should also include an accurate and objective
patient selection.4 Bendamustine is an alkylating agent
with properties of a purine analog and is approved for the
treatment of chronic lymphocytic leukemia (CLL) and
indolent NHL. Bendamustine  was also studied in aggres-
sive lymphomas; several phase II studies of BR (ben-
damustine in association with rituximab) in patients with
relapsed refractory DLBCL showed promising efficacy
with overall good tolerance of this regimen in the salvage
setting.5-7 The activity of BR was also tested with promis-
ing results in small phase II studies on untreated patients
who were generally considered  not eligible for standard
R-CHOP.8,9
In 2014, the Fondazione Italiana Linfomi (FIL) started a
phase II study to investigate the activity and the safety
profile of a combination regimen of BR for the initial ther-
apy of patients with DLBCL who were not eligible to
receive standard anthracycline-based therapy. In contrast
to  other studies, we included patients who were prospec-
tively classified as frail according to the  Comprehensive
Geriatric Assessment (CGA),10 and we evaluated a modi-
fied BR schedule. Based on available evidence, there is still
no standard treatment for this subset of patients, complete
response to therapy is approximately 15%,11 and, even if
rituximab is used, the median OS is approximately 20
months.12
Methods
Study design and objectives
This is a phase II open-label, non-randomized study to inves-
tigate activity and safety of BR combination therapy in elderly
patients with DLBCL, prospectively defined as frail according to
the CGA. The study was approved by the local ethics commit-
tees.
Patient eligibility
Eligible patients were elderly frail patients aged 70 years or
over with a newly diagnosed, histologically proven DLBCL. All
patients were prospectively evaluated by the CGA, as originally
reported as part of pre-therapy assessment. Briefly, the CGA
used was based on the assessment of Activities of Daily Living
(ADL), Instrumental Activities of Daily Living (IADL), and
Cumulative Illness Rating Scale-Geriatric (CIRS-G). Patients
were classified as frail if the following criteria were met: in
patients aged between 70 and 80 years,  ADL<4 or IADL<5 or 1
grade 3 comorbidity or >8 grade 2 comorbidities were required;
in patients older than 80 years, ADL>5 or IADL>6 or 5-8 grade
2 comorbidities were required10 (Table 1). A full list of inclusion
criteria and study procedures is available  in the Online
Supplementary Appendix.
Treatment
Patients received bendamustine (90 mg/m2, d1-2) combined
with rituximab (375 mg/m2, d1) every 28 days. Patients with
age-adjusted International Prognostic Index (aaIPI) equal to 0
and non-bulky disease received 4 cycles of BR followed by 2
cycles of rituximab. All other patients received 6 cycles of BR
followed by 2 cycles of rituximab. Bendamustine was supplied
for free by Mundipharma. The use of consolidation radiothera-
py was allowed. Prophylaxis with valacyclovir and cotrimoxa-
zole was mandatory. The use of granulocyte-colony stimulating
factor (G-CSF) and erythropoietin was recommended. 
Statistical analysis
The main study end point was the complete remission rate
(CRR) that was calculated on the efficacy population (EP; i.e.
patients receiving at least 2 courses of BR) using Cheson 1999
criteria.13 A further end point was the rate of grade 3-4 extra-
hematologic  adverse events (eeAEs) calculated on the safety
population (SP; i.e. all patients who have received at least one
dose of study medication) using CTCAE v.4.0 (Common
Terminology Criteria for Adverse Events). Secondary end points
were progression-free survival (PFS) and overall survival (OS).14
The study was conducted according to a Simon 2-stage
design. The null hypothesis (p0) for CRR was set to 0.15.11 With
a type I error of 0.05 and a type II error of 0.10, and considering
the alternative hypothesis (p1) at 0.35, at least 4 CRs were
required after the enrollment of the first 19 cases. With the full
enrollment of the 44 cases, at least 11 patients in CR were
required to confirm  activity of the combination to be promising.
Considering a 10% drop-out rate, the final study enrollment was
set at 49 patients.
Maximum tolerated toxicity rate for eeAEs was set at 30%.
Considering an alpha error of 0.05, and according to the 2-stage
Simon design, the study had to be stopped if grade 3-4 events
were observed in 12 or more patients out of the first 19 enrolled.
With the enrollment of the planned 44 patients, a maximum
number of 20 patients with grade 3-4 eeAEs were allowed.
Results
Patients
From February 2012 to February 2014, 49 patients were
enrolled into the study by 24 Italian centers. Three patients
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Table 1. Comprehensive Geriatric Assessment criteria for definition of
fit, unfit and frail patients.
                                      FIT                            UNFIT                  FRAIL
ADL                                        6                                       5*                            ≤ 4
IADL                                       8                                      7-6*                          ≤ 5
CIRS**                        0 score=3-4                    0 score=3-4           1 score=3-4
                                      < 5 score=2                    5-8 score=2          > 8 score=2
Age                                                                              ≥ 80 fit                  ≥ 80 unfit
ADL: Activity of Daily Living; IADL: Instrumental Activities of Daily Living; CIRS:
Cumulative Illness Rating Scale. *Residual function. **Scores are referred to severity
of assessed comorbidities (as reported by Tucci et al.10)
were considered ineligible due to violation of inclusion cri-
teria (one patient was not confirmed as frail, one did not
undergo CGA evaluation, one case was HCV positive).
One additional patient was excluded from the study analy-
sis due to death before treatment start. The clinical charac-
teristics of the remaining 45 patients are shown in Table 2.
A full list of comorbidities with observed rates is provided
in Online Supplementary Table S1.
Feasibility and Efficacy
Treatment was started in 45 eligible patients. Nine
patients were at low risk (aaIPI 0 and non-bulky disease)
and had to receive 4 BR cycles followed by two doses of
rituximab. All the other patients (n=36) were at high risk
and had to receive all 6 BR cycles followed by two doses
of rituximab. Overall, 25 patients received all planned ben-
damustine doses (55%); 7 of 9 at low risk, and 18 of 36 at
high risk. Treatment was discontinued due to progressive
disease (12 patients), eeAEs (8 patients) and physician's
decision (7 patients). Four non-bulky patients (3 with stage
I-II, 1 with stage IV) received consolidation radiotherapy.
In 4 high-risk cases, treatment was interrupted before
administration of the 2 consolidation doses of rituximab.
Three additional patients interrupted treatment after cycle
4 (n=1) and 5 (n=2) due to physician's decision. The calcu-
lated administered dose intensity for rituximab and ben-
damustine was 0.990 (25-75 percentiles: 0.901-1.016), and
0.996 (25-75 percentiles: 0.877-1.017).
The efficacy analysis was based on all 45 cases. After
the enrollment of the first 19 patients, 5 CRs were
observed and the accrual to study stage 2 opened. Overall,
24 patients achieved a CR at the end of treatment (53%;
95%CI: 38-68%), 4 patients achieved a partial remission
(PR), one patient had a stable disease (SD), 13 patients had
progressive disease (PD), and in 3 patients response was
not evaluable (due to AEs: pelvic fracture, pneumonia,
heart attack). The overall response rate (ORR) was 62%
(95%CI: 47-76%). The observed CRR was higher than
that initially required for efficacy assessment by the study
design (Table 3).
Safety
The safety analysis was available for all 45 eligible
patients and for 244 cycles. Thirty-five grade 3-4 AEs were
reported in 23 patients (51.1%; 95CI: 35.8-66.3%); the
most frequent grade 3-4 AE was neutropenia with 17
events (37.8%) (Table 4). Though not mandatory, G-CSF
was used in 26 patients (58%; 95CI: 42-72%).
The rate of grade 3-4 eeAE was monitored during stage
1 and stage 2 of the study. Overall, grade 3-4 eeAEs were
reported in 7 patients (15.6%; 95CI: 6.5-29.5%) and grade
3-4 hematologic AEs were reported in 21 cases (46.7%;
95CI: 31.7-62.1%). The most frequent grade 3-4 eeAE was
infection (n=2 patients, 4.4%); no grade 4 infections were
reported.  A detail of all reported AEs is provided in Table
4. Both for study stage I and stage II, the rate of grade 3-4
eeAEs never fell beyond the maximum  rate allowed.
Survival analysis
The median follow up was 33 months (range 1-52).
Thirty-two patients experienced PD,  including 13 PD at
the end of induction therapy, 12 relapses, and 7 deaths for
causes unrelated to lymphoma (pneumonia, heart failure,
hepatocarcinoma, neurological disorder, respiratory disor-
der, cachexia, unknown).  The 2-year PFS was 38%
(95%CI: 24-51%) and the median PFS was 10 months
(95%CI:  7-25%) (Figure 1).
Overall, 24 patients died: 8 during treatment and 16 dur-
ing follow up. Cause of death was lymphoma progression
in 14 patients (58%), and unrelated causes in 8 patients
(the 7 deaths reported above, plus one patient who died
due to secondary acute myeloyd leukemia after lym-
phoma progression). Two-year OS was 51% (95%CI: 35-
65%) and median OS was 30 months (95%CI: 10-NA).
The results of the CGA scales used during patients’ base-
line assessment were correlated with OS and PFS in uni-
variate analysis, and no association was found (Table 5). In
addition, no association was found between results of
CGA scales and safety results (data not shown).
Discussion
We report the results of a phase II study to investigate
the activity and toxicity of a combination regimen of ritu -
ximab and bendamustine for the initial treatment of
patients with DLBCL who were classified as frail based on
BR in frail elderly patients with DLBCL
haematologica | 2018; 103(8) 1347
Table 3. Response after planned rituximab plus bendamustine treat-
ment.                            Status                   Missing                   N (%)
Response               R8+B6 (n=36)         R6+B4 (n=9)          Total (n=45)
                                     N (%)                      N (%)               N (%,  %95CI)
CR                                      19 (53)                        5 (56)                  24 (53; 38-68)
PR                                       4 (11)                              -                          4 (9; 2-21)
ORR                                                                                                      28 (62; 47-76)
SD                                        1 (3)                               -                          1 (2; 0-12)
PD                                       9 (25)                         4 (44)                  13 (29; 16-44)
Not assessed                    1 (3)                               -                          1 (2; 0-12)
Death in treatment *      2 (6)                               -                          2 (4; 1-15)
*Dead for heart failure and pneumonia. R8+B6: rituximab for 8 cycles and bendamus-
tine for 6 cycles; R6+B4: Rituximab for 6 cycles and bendamustine for 4 cycles; n/N::
number; CI: Confidence Interval; CR: complete remission; PR: partial remission; ORR:
overall response rate; SD: stable disease; PD: progression disease.
Table 2. Baseline characteristics of patients eligible for the study
(n=45).
                                     Status                      Missing                  N (%)
Sex                                       Male                                   -                            26 (58)
Age (years)             Median (range)                         -                         81 (71-89)
Hb (g/dL)                 Median (range)                         -                     12.9 (7.8-16.1)
Stage                                       I                                       -                             7 (16)
                                                II                                                                   10 (23)
                                                III                                                                   6 (14)
                                                IV                                                                   22 (48)
ECOG PS                              >1                                     1                           16 (36)
ENS                                        >1                                     -                            11 (24)
LDH                                    >ULN                                  -                            16 (36)
IPI                                          3-5                                    1                           25 (57)
CGA                    Unfit with age ≥80 years                 -                            35 (78)
                                               frail                                                                 10 (22)
LVEF (%)                 Median (range)                        4                        60 (43-70)
Hb: hemoglobin; ECOG PS: Eastern Cooperative Oncology Group Performance Status;
ENS: extra nodal site; LDH: lactate dehydrogenase; ULN:upper limit of normal; IPI:
International Prognostic Index; CGA: comprehensive geriatric assessment; LVEF: left
ventricular ejection fraction.
a CGA. With the observed 53% CR rate, and with the
15.6% rate of grade 3-4 eeAEs, the study met its primary
objectives and shows  the promising activity of the com-
bination in a difficult-to-treat patient population
Besides the analysis of the main study end points
(response rate and safety), we acknowledge that the small
sample size of this study does not allow  any firm conclu-
sions to be drawn on the interpretation of secondary end
points, and in particular on PFS and OS data. Moreover,
the lack of a centralized histology review and cell of origin
analysis does not allow us to present any hypothesis on
the differential activity of bendamustine and rituximab
combination among DLBCL subtypes.
Since the activity of bendamustine in DLBCL was first
documented by Weidmann et al.,15 several phase II and
retrospective studies have been published to assess the
activity and the safety profile of this combination. In the
first prospective studies on relapsed refractory patients,
bendamustine was used at higher doses (120 mg/m2/d)
and with a shorter interval between cycles.5-7 In these tri-
als, the ORR ranged between 46% and 63% (CR 15-37%)
and the median PFS between 3.6 and 6.7 months (Table 6).
Park et al.8 recently published the results of a small phase
II trial of bendamustine at 120 mg/m2 in combination with
rituximab in untreated older patients (>65 years) who
were poor candidates for R-CHOP. Among the 23 enrolled
patients, the median age was 80 years, the ORR and the
CRR were 78% and 52%, respectively, but the median
PFS and OS were only 5.4 and 10 months, respectively. In
our study, in consideration of the patients’ age and frail
status, we opted for a regimen with bendamustine at a
lower dose of 90 mg/m2 combined with standard ritux-
imab doses, and administered every four weeks. Looking
at our results, this choice did not seem to significantly
reduce treatment activity compared to more intense pub-
lished BR regimens. Conversely, the adoption of a less
intense BR combination was well tolerated and was a
good choice for patients who were prospectively identi-
fied as frail. Comparing our data with those from prior
phase II reports, it should also be acknowledged that Park
et al. did not include stage I disease and had more poor
performance status patients, while Weidmann et al. had
more early stage patients, and a higher median age (85
years). Our data should also be compared with a previous
analysis of 99 elderly frail patients with DLBCL who were
analyzed in a prospective observational study.12 The
S. Storti et al.
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Table 4. Overall toxicities according to CTCAE v.4.0 categories with grade.
                                                                                     All grades                                                     Grade 3                                             Grade 4
                                                                            n                          %                                    n                         %                              n                     %
Anemia                                                                              20                             44.4                                          1                              2.2                                    0                        0.0
Leucopenia                                                                      19                             42.2                                          3                              6.7                                    2                        4.4
Neutropenia                                                                    29                             64.4                                          8                             17.8                                   9                       20.0
Thrombocytopenia                                                        20                             44.4                                          4                              8.9                                    0                        0.0
Febrile neutropenia                                                       3                               6.7                                           0                              0.0                                    1                        2.2
Infections                                                                         9                              20.0                                          2                              4.4                                    0                          0
Fever                                                                                  2                               4.4                                           0                              0.0                                    0                        0.0
Cardiac disorders                                                           4                               8.9                                           1                              2.2                                    1                        2.2
Gastrointestinal disorders                                          14                             31.1                                          0                              0.0                                    0                        0.0
General disorders and 
administration site conditions*                                  5                              11.1                                          1                              2.2                                    0                        0.0
Hepatobiliary disorders                                                2                               4.4                                           0                              0.0                                    0                        0.0
Metabolism and nutrition disorders                         3                               6.7                                           1                              2.2                                    0                        0.0
Nervous system disorders                                           4                               8.9                                           0                              0.0                                    0                        0.0
Renal and urinary disorders                                        4                               8.9                                           1                              2.2                                    0                        0.0
Skin and subcutaneous tissue disorders                 9                              20.0                                          0                              0.0                                    0                        0.0
Vascular disorders                                                         2                               4.4                                           0                              0.0                                    0                        0.0
Other (specify) **                                                         4                               8.9                                           0                              0.0                                    0                        0.0
CTCAE: Common Terminology Criteria for Adverse Events; n: number. *Asthenia; laboratory abnormalities; fever. **Other - Grade 1: epistaxis and flu; Grade 2: accidental fall
and cough.
Figure 1. Estimated progression-free survival (PFS) with 95% confidence inter-
val (gray area).
majority of frail subjects of this study were treated with
rituximab-containing therapy (39%) and 31 of them also
received an anthracycline-containing regimen.
Considering only the patients who were treated with
chemo-immunotherapy, the 2-year and median OS were
48% and 20 months, respectively. These data compare
favorably with those observed in the current study that
used a more strict definition of frailty (i.e. unfit patients
with intermediate profile at CGA were not included) and
were obtained without the use of doxorubicin. 
When this trial was started, data from a large observa-
tional study on 173 consecutive elderly patients with
DLBCL were already available. These suggested that the
use of chemotherapy regimens with curative intent were
not able to improve patients’ survival compared to pallia-
tive therapies for the subgroup of patients who were clas-
sified as frail according to the same CGA that we adopted
in this trial.10 Based on this observation, we considered
frail those patients ineligible to receive anthracycline-con-
taining regimens, also if administered at lower doses, and
identified an unmet need in the search of active therapies
in this subset of patients. Unfortunately, lacking a ran-
domized comparison, we cannot draw any conclusion on
the relative efficacy of the BR regimen in comparison with
other immunochemotherapy options. Due to its favorable
safety profile, however, the use of a BR combination
seems an excellent option and should be set as a reference
to identify more effective treatment strategies in future tri-
als. Regarding safety, the recent experience with BR in fol-
licular lymphoma reported an increase in toxicities; with
the limitations of a small number of patients, in our pop-
ulation, BR was manageable and safe; the two deaths due
to second malignancies is not an unexpected finding in a
very elderly population.
In order to further improve these results, additional
efforts should be made to attempt to increase the response
rate and to prolong the short duration of response.  New
drugs such as lenalidomide and  ibrutinib have shown
activity against DLBCL, are both associated with an excel-
lent safety profile,16,17 and could  be used to improve the
results with an acceptable toxicity. A phase II trial of ritux-
imab in association with a lenalidomide combination in
elderly frail patients is currently being conducted by our
group and actively recruiting patients (clinicaltrials.gov iden-
tifier: 02955823). In addition,  the published results of the
REMARC trial has  demonstrated, for the first time after
several unsuccessful attempts with other drugs,18 that a
maintenance therapy with lenalidomide in elderly patients
with DLBCL who responded to initial immunochemother-
apy is associated with a reduced risk of disease progression
compared to observation.19 Finally, our study is part of a
larger project for elderly patients with DLBCL for whom a
preliminary CGA is required to define patient fitness status
and to adapt treatment goals accordingly. Patients prospec-
tively enrolled in this so called “elderly project” are evalu-
ated by a simplified version of the CGA20 and are catego-
rized into one of three groups: fit, unfit and frail (clinicaltri-
als.gov identifier: 02364050). Fit patients are then offered a
standard R-CHOP treatment with curative intent, and unfit
patients are considered better candidates for adapted R-
CHOP regimens with reduced drug doses to achieve a cure
with reduced toxicity. Finally, no clear benefit was
observed for frail patients  treated with curative intent
compared with those treated with palliative intent, and
there was no standard or reference regimen.21 To the best
of our knowledge, the elderly project is the first attempt to
try to objectify the treatment approach to elderly patients
with lymphoma and to promote clinical research in this
population. With our study, and with the adoption of a
prospective definition of patient fitness, we have been able
to show that, also in the population of frail patients, the
use of a low toxicity regimen allows a cure of the lym-
phoma to be achieved in a good proportion of patients.
These data, along with the adopted CGA evaluation, help
BR in frail elderly patients with DLBCL
haematologica | 2018; 103(8) 1349
Table 5. Association of age, geriatric scales and IPI with OS and PFS
(univariate analysis).
Variable            1yr-OS %          Log-rank          1yr PFS %          Log-rank
                           (95CI)                  P                 (95%CI)                 P
Age                                                        0.694                                                  0.685
≤80                   68 (29-88)                                        60 (25-83)                    
>80                   62 (44-76)                                        46 (29-61)                    
ADL                                                       0.335                                                  0.536
6                        70 (48-85)                                        56 (35-73)                    
5                        50 (21-74)                                         25 (6-50)                     
0-4                     63 (23-86)                                        62 (23-86)                    
IADL                                                     0.350                                                  0.020
8                         33 (5-68)                                          33 (5-68)                     
6-7                     71 (49-85)                                        56 (35-73)                    
0-5                     62 (32-82)                                        43 (18-66)                    
IPI                                                         0.531                                                  0.581
1-2                     77 (50-91)                                        58 (33-76)                    
3-5                     52 (31-69)                                        40 (21-58)                    
yr: year; CI: Confidence Interval; ADL: Activities of Daily Living; IADL: Instrumental
Activities of Daily Living; IPI: International Prognostic Index; OS: overall survival; PFS:
progression-free survival.
Table 6. Summary of prospective studies of bendamustine in association with rituximab in diffuse large B-cell lymphoma.
Author                                         Year                 Patients                 Phase         Benda dose            Days              CRR%             ORR%                 mPFS
                                                (medAge)                                                                 mg/m2                                                                                                                                                                           months
Ohmachi et al.6                                    2013                     59 (65)                         R/R                      120                         21                      37.7                     62.7                          6.7
Vacirca et al.7                                        2014                     48 (74)                         R/R                  90/120*                     28                      15.3                     45.8                          3.6
Weidmann et al.9                                 2011                     13 (85)                       Untr.                     120                         21                       54                        69                           7.7
Park et al.8                                             2016                     23 (80)                       Untr.                     120                         21                       52                        78                           5.4
Current report                                    2016                     45 (81)                       Untr.                      90                          28                       53                        62                            10
*Bendamustine (Benda) dosage 90 mg/m2 was administered for the first 2 patients on study.  Following the US FDA approval, the dosage was amended to 120 mg/m2. R/R:
relapsed/refractory; medAge: median age; Untr: untreated; CRR: complete remission rate; ORR: overall response rate; mPFS: median progression-free survival.
to define new reference points for  future therapeutic
development in an otherwise highly heterogeneous and
difficult-to-treat population. 
In conclusion, considering our results, and the other
available data discussed above, we believe that the com-
bination of bendamustine and rituximab, even if not cur-
ative, is a good option for the treatment of elderly frail
patients with DLBCL, also when used at reduced doses
and administered at 4-week intervals as in our study.
Treatment of elderly frail patients remains a challenge for
the clinician, and the choice of treatment should be indi-
vidualized considering all available options and through
an accurate assessment of the risk-benefit ratio for each
single patient. At least as important as the choice of
treatment, a concerted effort should be made to adopt
validated tools to assess patient fitness status before
treatment start and to adapt treatment goals accordingly.
In this context, we recommend the use of the simplified
version of the CGA as  used in this study.
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